Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
Wednesday, Roche Holding AG (OTC:RHHBY) entered into a definitive agreement with Lonza Group Ltd (OTC:LZAGF) (OTC:LZAGY).
週三，羅氏控股股份公司（場外交易代碼：RHHBY）與隆沙集團有限公司（場外交易代碼：LZAGF）（場外交易代碼：LZAGY）簽訂了最終協議。
Under the agreement, Lonza will acquire the Genentech manufacturing facility in Vacaville, California, for $1.2 billion in conjunction with a manufacturing agreement and related quality services and warehousing.
根據該協議，Lonza將以12億美元的價格收購位於加利福尼亞州瓦卡維爾的基因泰克製造工廠，同時收購製造協議以及相關的優質服務和倉儲。
Under the terms of the agreement, Lonza will offer approximately 750 Genentech employees at the Vacaville facility employment, and the products currently produced at the site by Roche will continue to be supplied by Lonza for a transition period.
根據協議條款，隆沙將爲瓦卡維爾工廠的大約750名基因泰克員工提供就業機會，而羅氏目前在該工廠生產的產品將在過渡期內繼續由龍沙提供。
The acquisition will increase Lonza's large-scale biologics manufacturing capacity. The Vacaville (US) facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics manufacturing sites in the world by volume.
此次收購將提高Lonza的大規模生物製劑製造能力。瓦卡維爾（美國）工廠目前的生物反應器總容量約爲33萬升，是世界上體積最大的生物製劑生產基地之一。
Lonza plans to invest approximately CHF 500 million in additional Capex to upgrade the Vacaville (US) facility and enhance capabilities to satisfy demand for the next generation of mammalian biologics therapies.
Lonza計劃投資約5億瑞士法郎的額外資本支出，以升級瓦卡維爾（美國）的設施並增強能力，以滿足對下一代哺乳動物生物製劑療法的需求。
The products currently manufactured at the site by Roche will be supplied by Lonza, with committed volumes over the medium term, phasing out over time as the site transitions to serve alternative customers.
羅氏目前在該工廠生產的產品將由Lonza提供，承諾在中期內批量生產，隨着工廠過渡到爲替代客戶提供服務，將逐步淘汰。
As the transaction is expected to be accretive to sales growth, Lonza has updated its mid-term guidance for 2024–2028.
由於該交易預計將促進銷售增長，Lonza更新了其2024-2028年的中期指導。
Its sales growth range was set at 11–13% CAGR in CER and has now been updated to 12 – 15%.
按恒定匯率計算，其銷售增長區間設定爲11-13％的複合年增長率，現已更新至12-15％。
Mid-term guidance for core EBITDA margin and ROIC remains unchanged.
核心息稅折舊攤銷前利潤率和投資回報率的中期指導保持不變。
The transaction is expected to close by H2 2024.
該交易預計將於2024年下半年完成。
譯文內容由第三人軟體翻譯。